Skip to content

EPS (Diluted) at other companies

Intel logo
IntelINTC
-$0.73-284%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.14-52.9%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0.60+1,100%
Mobileye Global Inc. logo
Mobileye Global Inc.MBLY
-$4.68-3,500%
Polaryx Therapeutics, Inc.
 logo
Polaryx Therapeutics, Inc. PLYX
-$0.05+54.5%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-$0.34+19.0%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s EPS (diluted)?
Rafael Holdings, Inc. (RFL) reported EPS (diluted) of -$0.08 in Q1 2026.
How has Rafael Holdings, Inc.'s EPS (diluted) changed year-over-year?
Rafael Holdings, Inc.'s EPS (diluted) increased by 57.9% year-over-year, from -$0.19 to -$0.08.
What is the long-term trend for Rafael Holdings, Inc.'s EPS (diluted)?
Over 3 years (2021 to 2025), Rafael Holdings, Inc.'s EPS (diluted) has grown at a -10.5% compound annual growth rate (CAGR), from -$1.48 to -$1.06.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.